FDA Resubmission Path for Tab-cel Keeps Atara’s (ATRA) Regulatory Timeline Alive
medical research 7 ©Belova59 – pixabay.com Atara Biotherapeutics said the FDA outlined a potential pathway for resubmitting the…
FDA Rejects CAPR’s Cell Therapy BLA for Genetic Disorder, Stock Tanks
Shares of Capricor Therapeutics CAPR tanked 33% on Friday after it announced that the FDA issued a complete…